Les analogues de l'insuline : la place de la détémir (Levemir®) Insulin analogues : place of detemir (Levemir®)

Insulin detemir (Levemir®) is a soluble longacting human insulin analogue acylated with a 14-carbon fatty acid. Insulin detemir is 98-99 % albumin bound in plasma. It has a more predictable glucose-lowering effect than NPH insulin or insulin glargin. There is a doseresponse relationship, but at the dose of 0.4 units/ kg (an average normal dose), the duration of action reaches nearly 24 h. Therefore, detemir, most often injected once per day at bedtime, seems to be the ideal basal insulin in the basal-prandial therapy for type 1 diabetic patients. The boli of insulin, in order to cover the meals, may be done with a rapid acting human insulin and/or a fast acting analogue. In comparison with NPH insulin, detemir has been shown to reduce the risk of (severe) hypoglycaemias, particularly nocturnal (up to 50 %). Fasting hyperglycaemia is often lower, but it is not necessarily true for glycated haemoglobin. In addition, detemir has been associated with less weight gain than NPH insulin. Detemir is well tolerated and no specific safety concerns have been raised. Rev Med Brux 2006 ; 27 : 89-94